Investorideas.com newswire, breaking news for marijuana, cannabis and hemp stocks

Wednesday, 6 January 2021

Investorideas.com - Cannabis Stock News: Matica (CSE: MMJ) Forwards First Shipment of Cannabis to Manitoba

Investorideas.com - Cannabis Stock News: Matica (CSE: MMJ) Forwards First Shipment of Cannabis to Manitoba

Investorideas.com - Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry December 28th, 2020 - January 1st, 2021

Investorideas.com - Cannabis Deal Tracker: Investment and M&A Activity in the Cannabis Industry December 28th, 2020 - January 1st, 2021

Investorideas.com - Governor Cuomo Announces Marijuana Legalization Effort in 2021

Investorideas.com - Governor Cuomo Announces Marijuana Legalization Effort in 2021

Investor Ideas #Potcasts 513- #Cannabis News and #Stocks on the Move; (TSXV: $FLWR.V) (OTC: $MJNA) (OTCQB: $CTGL) (TSX: $AVCN.TO)

 


Investor Ideas #Potcasts 513- #Cannabis News and #Stocks on the Move; (TSXV: $FLWR.V) (OTC: $MJNA) (OTCQB: $CTGL) (TSX: $AVCN.TO)

 

Delta, Kelowna, BC, January 6, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/010621-StocksToWatch.mp3

 

Read this in full at

https://www.investorideas.com/news/2021/cannabis-potcasts/01061FLWR-MJNA-CTGL-AVCN.asp

 

Hear Investor ideas cannabis potcast on iTunes  

 

Hear the investor ideas potcast on Spotify

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we will be looking at a few public company announcements.

 

North America’s first research and development facility dedicated to advancing cannabis cultivation techniques and systems has been completed by The Flowr Corporation (TSXV: FLWR) and Hawthorne Canada Limited. Hawthorne is a subsidiary of the Hawthorne Gardening Company division of The Scotts Miracle-Gro Company (NYSE:SMG). Scotts Miracle-Gro is the world’s leading marketer of branded consumer lawn and garden products and indoor growing solutions. Flowr cultivates and sells premium cannabis to medical and adult-use markets in Canada, Europe and Australia.

 

Located on Flowr’s cultivation campus in Kelowna, British Columbia, Canada, the R&D Center includes state-of-the-art laboratories, indoor grow suites, and training areas in a single building. Flowr will test cultivation systems and techniques using Hawthorne’s advanced lighting, fertilization and irrigation systems, growing mediums, and research protocols. In addition, Flowr intends to focus its own research on cannabis genetics and integrated growing systems in line with its goal of delivering premium quality cannabis products through highly efficient cultivation.

 

“We built Hawthorne to help cultivators of all sizes grow quality plants with high levels of efficiency and consistency. Completing the industry’s only dedicated R&D facility gives us a distinct advantage. We will leverage Flowr’s cultivation expertise and our technical capabilities into real world testing and results that will make a difference to growers,” said Chris Hagedorn, SVP & General Manager of Hawthorne Gardening. “We are proud of this collaboration with Flowr, a leading international cannabis company, with extensive growing experience indoors, in greenhouses and at-scale outdoors. Flowr is also one of a few companies that have had experience growing diverse genetics in different countries. We believe this experience will benefit our companies and the growers we serve.”

 

“The completion of the R&D Center brings our work with Hawthorne fully to life and will help keep both companies on the leading edge of cannabis cultivation for years to come,” commented Lance Emanuel, President and Interim Chief Executive Officer of Flowr. “Operationalizing the R&D Center is a major accomplishment for our organization and strengthens our competitive advantage in cultivation. We believe the long-term success of Flowr will be rooted in our ability to maximize the cannabinoid and terpene expression of genetics without sacrificing yield. The work we will do at the R&D Center will help us build upon the success we’ve had producing high quality, premium cannabis like our award-winning, flagship-strain BC Pink Kush beloved by budtenders and consumers throughout Canada. Leveraging our work at the R&D Center will be imperative to our eventual entry into the United States once federally permissible by law.”

 

The R&D Center is the centerpiece of a strategic R&D partnership formed by Flowr and Hawthorne in March 2018. It brings two of the world’s leading experts together to be at the forefront of cannabis cultivation. The operations will be led by Dr. Deron Caplan, the first person in North America to earn a PhD focused on cannabis cultivation and production. Dr. Caplan was awarded his doctorate by the University of Guelph in August 2018 and is Flowr’s Director of Research and Development. The R&D Center will be staffed by Flowr’s scientists, five of whom have PhDs in various plant biology, plant genetics and plant biochemistry disciplines. Hawthorne R&D will lead the research design and methodology.

 

All requisite licensing from Health Canada has been obtained by Flowr and the expectation is that the R&D Center will be operating at full capacity in Spring 2021. Research has already begun conducting growing trials at scale using Hawthorne products.

 

Medical Marijuana, Inc. (OTC: MJNA) announced that its subsidiary HempMeds® has launched its first-ever products containing cannabigerol (CBG) and cannabinol (CBN) as part of the Company’s recently updated brand strategy.

 

“When we founded HempMeds a decade ago, we were helping to create the entire CBD category. Since then, CBD has become the booming industry that we expected and acceptance for cannabinoids has come an incredibly long way in the last few years,” said HempMeds® Co-Founder Michelle Sides. “While our flagship RSHO products remain popular, we recognized it was time to expand alongside the industry and broaden our offerings as part of the company’s exciting new direction. We are confident that consumers will be excited about our new CBG and CBN products.”

Each 12-ounce bottle of HempMeds®’ RSHO® Calm Support is formulated to promote overall relaxation with 300 mg of CBN, 2,000 mg of CBD and 300 mg of Piperine, naturally derived from black pepper, to increase bioavailability.

 

For those looking for an additional boost of focus, each 12-ounce bottle of RSHO® Focus Support offers 1,500 mg of CBD, 1,500 mg of CBG and 300 mg of Piperine.

 

“It is amazing to think that there are over 100 lesser-known minor cannabinoids in the cannabis plant, each with its own potential benefits. With minor cannabinoids like CBG and CBN growing in popularity, they will likely take over more and more of the expected $47.2 billion global cannabis market. We look forward to continuing to expand and evolve our offerings in response to consumer demand, starting with these new products,” said HempMeds® CEO Raul Elizalde.

 

 

On December 30, 2020, Cannovation Center Israel Ltd. won Israeli Government Ministry of Economy grant to acquire 10,000 square meters (2.5 acres) of industrial land to build the Cannovation Center Israel at the Biopharma Park in Yeruham.

 

The Cannovation Center Israel is a unique platform that includes factories for the production of medical cannabis, botanicals, CBD, hemp, supplements, food, and cosmetic products; laboratories for quality assurance, research, development, and clinical trials; a logistics, distribution, import and export center; business development strategy services.

 

Citrine Global, Corp. (OTCQB: CTGL) operates in Israel through its wholly owned subsidiary, CTGL - Citrine Global Israel Ltd. ("Citrine Global Israel"), which focuses on Israeli technologies in the fields of healthcare, wellness, foodtech and medical cannabis.

 

Cannovation Center Israel Ltd. is 60%-owned by Citrine Global Israel Ltd. and Citrine Global Group views the establishment of the Cannovation Center Israel as a national project backed by grants and support from the Israeli government and the Yeruham local council, and is aiming to create an ecosystem and collaborations between companies, entrepreneurs, universities and partners from Israel and around the world.

 

Ora Elharar Soffer, CEO, Citrine Global Corp.: "We are proud to be the ones to establish the first operational innovation center of its kind for cannabis in the Biopharma Park in Yeruham with the support of the Israeli government and Yeruham Local Council and take part in the realization of Tal Ohana's vision to turn Yeruham into the capital of medical cannabis. The Cannovation Center Israel will provide a comprehensive operational solution tailored to the requirements of the cannabis and botanical industry and is an important milestone that combines production, operations, technologies, and business development to leverage local and international collaborations. According to our strategy, we plan to build additional operational innovation centers working in this business model around the world."

 

Tal Ohana, Mayor of Yeruham: "We have been working with Ora Elharar Soffer and the Citrine Global Group and welcome the establishment of the innovative Cannovation Center Israel in the Biopharma Park in Yeruham. Our vision to turn Yeruham into the medical cannabis capital, through the Green-Negev project which I have been leading in the last few years, is becoming a reality. We receive support from the Israeli government and leading companies and entrepreneurs. In the last year, we have established a start-up incubator for cannabis technologies with the assistance of the Innovation Authority and in partnership with the pharmaceutical company Perrigo, which has a factory in Yeruham, and with Israeli Cannabis Company BOL. The incubator is already active, and the expected volume of investments is NIS 150 million for the operation of the incubator in the coming years. In addition, we received approval from the Ministry of Economy to allocate land and support factories' construction, which includes a 30% return on investment in the construction of the factory, a subsidized industrial area, reduced corporate tax, subsidy for senior employees' salaries, and more."

 

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announced that the Company has entered into a master services agreement with the University Health Network for projects to be performed by Dr. Peter Carlen as the principal investigator related to epilepsy. Additionally, the company has completed the technical transfer and first pharmaceutical pilot production of its epilepsy drug candidate at Altea Farmaceutica S.A. in Bogota, Colombia, a major step required for the final preparation for its registration and commercialization in South America.

 

The epilepsy research collaboration is lead by Dr. Peter Carlen, who is a Senior Scientist at the Krembil Research Institute at UHN and a world-renowned researcher in the field of epilepsy. Dr. Carlen's laboratory will be analyzing Avicanna's RHO Phyto and pharmaceutical cannabinoid-based products for their efficacy in the treatment of seizures.

 

The partnership will also co-develop a high throughput electrophysiological testing system for the evaluation of multiple cannabinoid ratios and in combination with standard epileptic drugs. In addition, the system will examine standard anti-seizure drugs for their efficacy in the model and determine the potential synergistic value of adjunctive cannabinoids, and cannabinoids as monotherapy in treating seizures in this in vitro setting.

 

Dr. Peter Carlen commented: “The Carlen lab is very pleased to research the relationships between the premium medicinal cannabinoid products of Avicanna and their effects on epilepsy. Also, in collaboration with Avicanna, we are developing a high-throughput platform to assess these interactions. We think that medical cannabinoids will have a major impact on brain health, particularly as we gain greater understanding of their effects on brain function in health and disease.”

 

The services to be performed under the Master Services Agreement will be provided on an exclusive basis and Dr. Carlen's laboratory has agreed to not conduct testing on any formulations or products similar to the Products for a period of two (2) years. All intellectual property created under the Master Services Agreement will remain the sole property of Avicanna. The research collaboration is further expanded to include electrophysiological studies of medical cannabinoids on 3D human cerebral organoids and neuroglial cultures with the support of a two-year Mitacs Accelerate program grant.

 

Avicanna also completed its first pharmaceutical level production of its first epilepsy drug candidate under GMP and ICH guidelines which are necessary for sanitary drug registration. The formulation developed by Avicanna includes active pharmaceutical ingredients which are cannabinoids produced by Avicanna’s subsidiary Santa Marta Golden Hemp S.A.S. The final GMP manufacturing took place at Avicanna’s exclusive manufacturing partner’s, Altea’s, facility in Bogota, which is a Health Canada and ANVISA (Brazil) approved GMP facility. The completion of this pharmaceutical production now allows Avicanna to proceed with drug registrations for epilepsy across several markets in South America including Colombia and Brazil.

 

Aras Azadian, CEO of Avicanna, commented: “We are pleased to demonstrate our dedication to world-class research and to take this stride in our epilepsy research program with a leading Canadian research institute and Dr. Carlen. This multi-level partnership will help to further study our current medical cannabis and pharmaceutical products, and will support the development and increase the depth of our pharmaceutical pipeline. Additionally, the completion of our first pharmaceutical production marks a milestone event in our drug development plans and highlights our capabilities to scale our drug formulations from bench top to industrial manufacturing.”

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  


Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Monday, 4 January 2021

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 512 - 2020 Round Up

 

Investor Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 512 - 2020 Round Up

 


Delta, Kelowna, BC, January 4, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca  release today’s podcast edition of  cannabis news and stocks to watch plus insight from thought leaders and experts.

 

Listen to the podcast:

https://www.investorideas.com/Audio/Podcasts/2021/010421-StocksToWatch.mp3

 

Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/01041Round-Up-2020.asp

 

Hear the investor ideas potcast on Spotify

Hear Investor ideas cannabis potcast on iTunes  

 

Today’s podcast overview/transcript:

 

Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.

 

In today’s podcast we will be taking a quick look back at 2020 and the year’s main highlights.

 

 

Sales Growth:

          While COVID-19 has had a significantly negative impact on most industries this year, the cannabis sector has seen substantial sales growth month over month as the year has progressed. This can be attributed to many factors related to COVID measures as well as to the success and growth of the industry itself.

 

One of the first contributing factors that helped sales growth this year was the very different place the entire industry was at the start of 2020 when compared to years previous. Supply issues were a massive factor contributing to lower sales in 2018 and 2019 in Canada and in the US, multi-state operators were still in the process and gaining the footing and building out their infrastructure. Looking at the start of 2020 we saw in Canada that many of the large scale producers who struggled in the first two years finally hit their stride as far as product supply levels and quality and consistency of their products. We also began to see the development of a premium bud segment in the industry through partnerships with smaller niche cultivators and the Cannabis 2.0 products that had been in the wing for months finally started hitting retail shelves. The retail development  within Canada was also in a much more stable and built out position starting in 2020 than in other years with private retail stores in BC and Ontario, the two most populous provinces, seeing massive growth.


Image courtesy of: MJBIZ Daily

 

With the industry being in a much better starting position entering 2020, the next big factor to impact sales was obviously COVID-19 and lockdowns.

 

In Canada with so many people stuck at home due to lockdown procedures and mahy receiving government aid checks from being out of the work, we saw a massive spike in Cannabis usage and sales as many who were on the fence socially about this substance in years previous changed their perception.

 

This was also massively aided by Cannabis businesses being deemed essential in both the US and Canada as well as other parts of the world where legal cannabis operations are in place. This change from Illegal to essential brought many new consumers to the market and has helped remove some of the long standing stigma surrounding the industry.

 

These contributing factors which aided to sales gave many companies in the industry the much needed revenue boost they had been waiting for and allowed many companies the time and financial resources to begin expansion and innovation.

 

 

Industry Innovation:

          Increased sales and revenues in many ways helped stabilize what was previously a very unstable industry, which allowed many to use the time to innovate and expand.

 

We saw a plethora of Cannabis 2.0 products that had been stuck in development hell for months finally begin hitting shelves and as more products hit retail stores we saw competitors continue to innovate and adapt their products to consumers needs as the year progressed.

 

Not only did many companies innovate with regards to their products but we also saw many retailers build out their online capabilities and begin offering delivery and cubside services, where regulators allowed, which again helped increase their customer share and overall sales.

 

Now most of the US and Canadian cannabis retail sector offers online sales, delivery or curbside pickup as well as touchless transactions and interactive menus, all features that had been slowly developing over the last two years but suddenly saw a massive jump in 2020 due to the necessity for innovation COVID created.

 

This also translated to the underserved medical community who saw massive growth in Telemedicine usage globally and in medical cannabis countries, there were serious adjustments to the overall medical industry which now allows for easier access to cannabis medication, delivery and curbside pick up options, telemedicine prescription and information access as well as a massive growth in product selection and inventory.

 

Continued Legalization and Social Acceptance:

          While I had already mentioned the massive social change created from Cannabis businesses being deemed essential this year, there was also another huge shift in the US, as well as globally towards cannabis reform policy and general drug reform policy.

 

This year saw many new states in the US vote for cannabis reform such as New Jersey, Montanna, Arizona and South Dakota, which all voted in favor of cannabis reform. We also saw states like Oregan set new drug policy precedent in the US by voting in favor of decriminalizing virtually all drugs and legalizing medicinal psilocybin.

 

On a global scale we saw more countries in South America extend or improve their cannabis drug policies in favour of import and export opportunities and increased medical availability. One of the largest holdouts as well as probably one of the largest potential markets, Mexico looks to have some sort of medical cannabis program in place in 2021, though regulatory progress has been slow so far. Even in South East Asia we have seen a growing leniency towards CBD products with some countries beginning the process of implementing a medical cannabis program, again most likely in 2021 or 2022.

 

In the EU, while we haven’t seen any major changes to the legal landscape, 2020 did help continue to build out the EU infrastructure for the medical and CBD industry and we have seen massive growth when it comes to import and export markets.

 

What’s Next?

          Looking ahead at 2021 and beyond there's a lot of hype and expectation surrounding the cannabis industry once again. One of the best things to come out of 2020 has been increased investor confidence and interest in this industry that saw a large investment slump since legalization in Canada in 2018. Many of the the industries largest companies are now trading back up at their regular prices and many smaller companies have had their best trading year to date.

 

          This increase in investor and consumer confidence in the industry should help push some of the last needed advancements in regulation and industry reform to boost the cannabis industry into the same social and societal acceptance of alcohol, if not allowing it surpass alcohol due to alcohol's many negative health impacts.

 

          Looking at the US in 2021 we can definitely expect more speculation and hype surrounding the idea of either Safe Banking Access or decriminalization of cannabis, at least one of these outcomes seems likely this year. We have seen many companies in both the US and Canada preparing for the merging of markets and with the implementation of at least Safe Banking Access a floodgate of investor capital becomes available to US based cannabis companies.

 

          Looking at Canada, there is expectation of regulatory reform surrounding delivery access in some provinces, private retail expansion as well a hopeful reevaluation of dosage and packaging restrictions, all of which would greatly benefit overall industry.

 

          Looking globally and at the industry as a whole, South American expansion of both medical and recreational markets seems inevitable as does expansion of the EU recreational market. There is a lot of excitement surrounding South East Asian markets establishing medical markets though this looks to be further out than 2021, though CBD products are very much in play. Finally we have seen a lot of infrastructure build out in Israel and parts of Africa, both of which could have massive impacts on the global pricing of Cannabis and CBD products as well as the import and export markets.

 

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.

 

Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

 

Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.

 

To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,   YouTube via Spreaker,  iHeartradio and Tunein.

 

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

 

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:

https://www.investorideas.com/About/Private_Policy.asp

 

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

 

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

 

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android 

Join our Investor Club https://www.investorideas.com/membership/

 

Contact Investorideas.com

800 665 0411

 

 


  



Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory

Psychedelic Stock News: Red Light Holland (CSE: TRIP) Signs Definitive Agreement with Mera Life Sciences and Files Annual Financial Statements

Psychedelic Stock News: Red Light Holland (CSE: TRIP) Signs Definitive Agreement with Mera Life Sciences and Files Annual Financial Statements